Kidney transplant rejection
Drug research and approvals for kidney transplant rejection: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 45 studies of kidney transplant rejection are recruiting on ClinicalTrials.gov, and Health Canada has authorized 5 drug trials for it since 2013.
- Recruiting worldwide: 45
- Trials authorized in Canada: 5
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 45 recruiting on ClinicalTrials.gov ↗- A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney TransplantNCT07613359 · Phase 2 · Takeda · starts Oct 27, 2026
- VEL-101 to Prevent Rejection After Kidney TransplantationNCT07290777 · Phase 2 · Asahi Kasei Therapeutics, Inc. · starts Aug 18, 2026
- Safety and Efficacy of the Bispecific T-Cell Engager (BiTE) in Kidney Transplant Recipients With Chronic Active…NCT07689578 · Phase 4 · Turun Song · starts Jul 30, 2026
- A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney TransplantNCT07508787 · Phase 2 · ITB-Med LLC · starts Jun 29, 2026
- Use of Extracorporeal Photopheresis in Kidney Transplantation: Effects on Antibody-Mediated RejectionNCT07663669 · Not reported · Centre Hospitalier Universitaire de Besancon · starts Jun 1, 2026
- Treatment of Antibody-Mediated Rejection (ABMR) With CarBelNCT06918990 · Phase 1 · National Institute of Allergy and Infectious Diseases (NIAID) · starts May 27, 2026
- Belimumab to Mobilise Memory B-cells From Secondary Lymhoid Organs to Improve Memory B-cell HLA-specificity Profiling…NCT07539857 · Phase 2 · Leiden University Medical Center · starts Apr 1, 2026
- A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney…NCT07412470 · Phase 2 / Phase 3 · Sanofi · starts Mar 13, 2026
- Peripheral and Intrarenal B Cell Study in Antibody Mediated Transplant Rejection : Phenotypic and Transcriptional…NCT07134491 · Not reported · Assistance Publique - Hôpitaux de Paris · starts Mar 13, 2026
- A Multicenter Randomized Controlled Trial to Treat Acute T Cell Mediated Rejection in Kidney and Kidney-Pancreas…NCT06474273 · Phase 3 · University of Sydney · starts Mar 13, 2026
Trials Authorized in Canada
Newest first; search them all in Canada trials| Feb 6, 2025 | A double-blind, placebo-controlled, multicenter, randomized phase 3 trial evaluating the efficacy and safety of felzartamab in kidney transplant recipients…FELZARTAMAB | Biogen | Ongoing |
| Dec 11, 2024 | A phase 2, double-blind, randomized, placebo-controlled, multicenter study to evaluate efficacy and safety of alxn2030 in adult patients with antibody mediated…ALXN2030 | AstraZeneca Pharmaceuticals LP | Ongoing |
| May 17, 2024 | A global, multicenter, randomized, double-blinded, placebo-controlled, phase 2 study to evaluate the safety, tolerability, and efficacy of efgartigimod ph20 sc…EFGARTIGIMOD (ARGX-113) PH20 SC | argenx US, Inc. | Ongoing |
| Dec 13, 2018 | A pivotal phase 3 trial to evaluate the safety and efficacy of clazakizumab for the treatment of chronic active antibody mediated rejection in kidney…CLAZAKIZUMAB | CSL | Ongoing |
| Apr 20, 2018 | Alloreactive t cell depletion as a novel treatment of refractory rejection in renal transplant patientsPDT-01 | HOPITAL MAISONNEUVE ROSEMONT | Pending |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA